Advertisement
Research paper| Volume 99, ISSUE 1, P55-61, February 1993

Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels

DOI:https://doi.org/10.1016/0021-9150(93)90050-5
Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels
Previous ArticleHypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels
Next ArticlePredisposition to LDL oxidation in patients with and without angiographically established coronary artery disease
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      It has been shown that triglyceride levels are one of the determinants of factor VII levels. In this study we have simultaneously evaluated, in a group of 102 healthy individuals, the different forms of factor VII, namely factor VII mass, factor VII coagulant activity, activated factor VII double-chain form and factor VII-phospholipid complex, in relation to triglyceridaemia. The data showed a highly significant correlation of factor VII mass, factor VII coagulant activity and factor VII-phospholipid complex with triglycerides. No correlation was observed between the activated factor VII double-chain form and triglycerides. These data, together with analysis of the linear and orthogonal regression slopes, suggest that increase of plasma factor VII coagulant activity as a function of plasma triglyceride levels is attributable to an increase in both mass and activity of factor VII and that the increase in activity is dependent on an increase of factor VII-phospholipid complex rather than activated factor VII double-chain form. The ratio between the slopes of the regression straight line of factor VII mass and factor VII-phospholipid complex in relation to triglycerides was 2.23 (95% confidence limits 1.74–2.50), thus indicating that the contribution of factor VII mass is prevalent over that of the factor VII-phospholipid complex.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Broze G.J.
        • Majerus P.W.
        Purification and properties of human coagulation factor VII.
        J. Biol. Chem. 1980; 255: 1242
        • Nemerson Y.
        Tissue factor and hemostasis.
        Blood. 1988; 71: 1
        • Dalaker K.
        • Prydz H.
        The coagulation factor VII in pregnancy.
        Br. J. Haematol. 1984; 56: 233
        • Dalaker K.
        • Hjermann I.
        • Prydz H.
        A novel form of factor VII in plasma from men at risk for cardiovascular disease.
        Br. J. Haematol. 1985; 61: 315
        • Meade T.W.
        • Chakrabarti R.
        • Haines A.P.
        • North W.R.S.
        • Stirling Y.
        • Thompson S.G.
        Haemostatic function and cardiovascular death: early results of a prospective study.
        Lancet,. 1980; 1: 1050
        • Meade T.W.
        • Mellows S.
        • Brozovic M.
        • Miller S.G.
        • Chakrabarti R.R.
        • North W.R.S.
        • Haines A.P.
        • Stirling Y.
        • Imeson J.D.
        • Thompson S.G.
        Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study.
        Lancet. 1986; 2: 533
        • Costantino M.
        • Merskey C.
        • Kidzma D.J.
        • Zucker M.B.
        Increased activity of vitamin K-dependent clotting factors in human hyperlipoproteinemia. Association with cholesterol and triglyceride levels.
        Thromb. Haemostas. 1977; 38: 465
        • Bruckert E.
        • Carvalho de Sousa J.
        • Giral P.
        • Soria C.
        • Chapman M.J.
        • Caen J.
        • Gennes J.L.
        Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia.
        Atherosclerosis. 1989; 75: 129
        • Mitropoulos K.A.
        • Miller G.J.
        • Reeves B.E.A.
        • Wilkes H.C.
        • Cruickshank J.K.
        Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men.
        Atherosclerosis. 1989; 76: 203
        • Scarabin P.Y.
        • Bonithon-kopp C.
        • Bara L.
        • Malmejak A.
        • Guize L.
        • Samama M.
        Factor VII activation and menopausal status.
        Thromb. Res. 1990; 57: 227
        • Meade T.W.
        Thrombosis and ischaemic heart disease.
        Br. Heart J. 1985; 53: 473
        • Carvalho de Sousa J.
        • Bruckert E.
        • Soria C.
        • Caen J.P.
        Phospholipase C sensitive FVII activity and FVII antigen in hypertriglyceridemia.
        Nouv. Rev. Fr. Hematol. 1989; 31: 13
        • Scarabin P.Y.
        • Bara L.
        • Samama M.
        • Orssaud G.
        Further evidence that activated factor VII is related to plasma lipid.
        Br. J. Haematol. 1985; 61: 177
        • Miller G.J.
        • Walter S.J.
        • Stirling Y.
        • Thompson S.G.
        • Esnouf M.P.
        • Meade T.W.
        Assay of factor VII activity by two techniques: evidence for increased conversion of VII to a-VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease.
        Br. J. Haematol. 1985; 59: 249
        • Dalaker K.
        • Smith P.
        • Arnesen H.
        • Prydz H.
        Factor VII-phospholipid complex in male survivors of acute myocardial infarction.
        Acta Med. Scand. 1987; 222: 111
        • Palmer R.N.
        • Gralnick H.R.
        Cold-induced contact surface activation of the prothrombin time in whole blood.
        Blood. 1982; 59: 38
        • Brozovic M.
        • Stirling Y.
        • Harricks C.
        • North W.R.S.
        • Meade T.W.
        Factor VII in an industrial population.
        Br. J. Haematol. 1974; 28: 381
        • Boyer C.
        • Wolf M.
        • Rothschild C.
        • Migaud M.
        • Amiral J.
        • Manucci P.M.
        • Meyer D.
        • Larrieu M.J.
        An enzyme immunoassay (elisa) for the quantitation of human factor VII.
        Thromb. Haemostas. 1986; 56: 250
        • Muller A.D.
        • Va Deijk W.A.
        • Devilee P.P.
        • Van Dam-Mieras M.C.E.
        • Hemker H.C.
        The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII.
        Br. J. Haematol. 1986; 62: 367
        • Poggio M.
        • Tripodi A.
        • Mariani G.
        • Mannucci P.M.
        Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas.
        Thromb. Haemostas. 1991; 65: 160
        • International Federation of Clinical Chemistry, Scientific Committee
        The theory of reference values: statistical treatment of collected reference values, determination of reference limits.
        J. Clin. Chem. Clin. Biochem. 1983; 21: 749
        • Dalaker K.
        • Skartlien A.H.
        • Prydz H.
        A new form of coagulation factor VII in plasma.
        Scand. J. Haematol. 1986; 36: 430
        • Dalaker K.
        • Ingebretsen O.C.
        • Rasmussen S.
        • Berge L.N.
        • Prydz H.
        Phospholipase C-sensitive factor VII activity in normal pregnancy.
        Acta Obstet. Gynecol. Scand. 1990; 69: 111
        • Dalaker K.
        Clotting factor VII during pregnancy, delivery and puerperium.
        Br. J. Obstet. Gynaecol. 1986; 93: 17
        • Hamsten A.
        Coagulation factors and hyperlipidaemia.
        Curr. Opinion Lipidol. 1991; 2: 266

      Article info

      Publication history

      Accepted: October 23, 1992
      Received in revised form: October 14, 1992
      Received: March 19, 1992

      Identification

      DOI: https://doi.org/10.1016/0021-9150(93)90050-5

      Copyright

      © 1993 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX